Actuate Therapeutics Inc

In a Stage 4 decline, price decisively broke a key support zone on high volume, maintaining lower highs and lower lows and confirming bearish control. The active Support Failure pattern signals that buyers can no longer absorb supply, and the medium-term bias remains Bearish. Short-term conditions align with continued downside pressure as price is extended below the declining 9 and 21 EMAs — execution is Sell Now. Key risks include a reclaim and acceptance above the EMAs, which would invalidate the bearish bias.

• ↑Elraglusib preclinical data (Sep 9, 2026) shows synergy with RAS inhibitors, driving further funding interest.
• ↑Zacks upgraded ACTU to Rank #2 (Buy), signaling increased confidence in future earnings.
• ↓Earnings yield at –3.0% suggests overvaluation against earnings potential.